Summary: This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic dermatitis.~The estimated duration is 4±1 weeks of screening and run-in period, followed by a 365 days double blinded treatment period with additional 84 days safety follow-up up t...